Compounds > cl 184005

Page last updated: 2024-11-07

cl 184005

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CL 184005: platelet activating factor antagonist; maybe useful in the treatment of gram-negative bacterial sepsis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	132290
CHEMBL ID	296973
MeSH ID	M0207971

Synonyms (17)

Synonym
cl-184,005
140466-18-8
gf2iph21j7 ,
unii-gf2iph21j7
thiazolium, 3-((3-((hydroxy(2-(methoxycarbonyl)-3-(tetradecyloxy)phenoxy)phosphinyl)oxy)phenyl)methyl)-5-methyl-, hydroxide, inner salt
cl 184005
cl-184005
CHEMBL296973 ,
((cl 184005))3-{3-[hydroxy-(2-methoxycarbonyl-3-tetradecyloxy-phenoxy)-phosphoryloxy]-benzyl}-5-methyl-thiazol-3-ium
3-{3-[hydroxy-(2-methoxycarbonyl-3-tetradecyloxy-phenoxy)-phosphoryloxy]-benzyl}-5-methyl-thiazol-3-ium
2-{hydroxy-[3-(5-methyl-thiazol-3-ylmethyl)-phenoxy]-dihydrogen phosphate}-6-tetradecyloxy-benzoic acid methyl ester(cl 184005)
bdbm50001754
(2-methoxycarbonyl-3-tetradecoxyphenyl) [3-[(5-methyl-1,3-thiazol-3-ium-3-yl)methyl]phenyl] phosphate
DTXSID40161407
thiazolium, 3-((3-((hydroxy(2-(methoxycarbonyl)-3-(tetradecyloxy)phenoxy)phosphinyl)oxy)phenyl)methyl)-5-methyl-, inner salt
2-(methoxycarbonyl)-3-(tetradecyloxy)phenyl (3-((5-methylthiazol-3-ium-3-yl)methyl)phenyl) phosphate
AKOS040748148

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Platelet-activating factor receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.5400	0.0043	0.7577	7.8000	AID224350
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID140215	Compound was evaluated for PAF-induced lethality in mouse (intraperitoneally at a dose of 1.0 mg/kg in saline 0.5 hr before lethal intravenous PAF challenge 75-150 mg/kg); 48/312	1992	Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26	Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
AID224350	Inhibition of PAF induced platelet aggregation in rabbit	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID224180	Concentration required to inhibit PAF (5*10e-8 M) induced platelet aggregation in rabbit platelet rich plasma(PRP) by 50%	1992	Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26	Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
AID166964	Compound was tested for protecting PAF-induced lethality in rabbit at a dose of 1 mg/kg (Out of 11)	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID135446	Compound was tested for protecting PAF-induced lethality in mouse at a dose of 1 mg/kg (Out of 10)	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID167026	Protection of PAF induced lethality in rabbit after intraperitoneal dose of 1 mg/kg in saline 0.5 hr prior to an LD90 of PAF	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
AID166973	Compound was tested for protecting PAF-induced lethality in rabbit at a dose of 5 mg/kg (Out of 5)	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID135444	Compound was tested for protecting PAF-induced lethality in mouse at a dose of 0.5 mg/kg (Out of 830)	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID166970	Compound was tested for protecting PAF-induced lethality in rabbit at a dose of 2.5 mg/kg (Out of 4)	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID138628	Compound was evaluated for PAF-induced lethality in mouse (intraperitoneally at a dose of 1.0 mg/kg in saline 0.5 hr before lethal intravenous PAF challenge 75-150 mg/kg)	1992	Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26	Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
AID224348	Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
AID140759	Protection of PAF induced lethality in mouse after intraperitoneal dose of 1 mg/kg in saline 0.5 hr prior to an LD90 of PAF	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	8 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.25 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.67	3	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.67	3	0	triazolobenzodiazepine	sedative
thiazoles [no description available]	3.08	5	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
web 2086 WEB 2086: structure given in first source; PAF antagonist	2.39	2	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	1.99	1	0	1,2,3-triazole
cv 3988 CV 3988: platelet activating factor antagonist; structure given in first source	2.38	2	0
cv 6209 CV 6209: platelet activating factor antagonist; structure given in first source	1.98	1	0
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	3.08	5	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
kadsurenone kadsurenone: platelet-activating factor receptor antagonist from Chinese herbal plant, haifenteng; structure given in first source; RN given refers to (2s-(2alpha,3beta,3aalpha))-isomer	2.67	3	0	benzofurans
l 652731 [no description available]	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Blood Poisoning [description not available]	0	1.98	1	0
Infections, Staphylococcal [description not available]	0	2.39	2	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	2.39	2	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	1.98	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	1.98	1	0
Blood Pressure, Low [description not available]	0	1.98	1	0
Bacterial Infections, Gram-Negative [description not available]	0	1.98	1	0
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	0	1.98	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	1.98	1	0